Prof Paul Van Houtte, speaking at the 2010 ELCC conference, discusses the use of targeted radiotherapy to treat lung cancer. Advances such as the use of stereotactic body radiation therapy (SBRT) have had significant effects on the outcome of treatments in stage one patients. Prof van Houtte also speaks about possible future advances in identifying specifically where treatment should be targeted and his preference for epidermal growth factors over vascular targeting agents.